GLAUKOS ANNOUNCES POSITIVE TOPLINE OUTCOMES IN PHASE 3 CONFIRMATORY TRIAL FOR EPIOXA™, ACHIEVING PRIMARY EFFICACY ENDPOINT AND DEMONSTRATING FAVORABLE TOLERABILITY AND SAFETY

Reuters · 10/16 20:05

Please log in to view news